Rucaparib maintenance therapy demonstrates PFS benefit for HRD-negative and HRD-positive ovarian cancer

Antonio WolffMikala EgebladAntonio C. Wolff and Mikala Egeblad were named co-directors of the Breast and Gynecologic Cancer Program at Johns Hopkins Kimmel Cancer Center.

August 08, 2025

Vol.51 No.31

Clinical Roundup

In phase III trial, epcoritamab regimen improves PFS in R/R follicular lymphoma

EPCORE FL-1 phase III trial results show that subcutaneous epcoritamab in combination with rituximab and lenalidomide reduced the risk of disease progression or death by 79% for patients with relapsed/refractory follicular lymphoma.

August 08, 2025

Vol.51 No.31

Clinical Conversation with The Cancer Letter

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

The first large cancer screening/early detection initiative to be launched in 2025—the NCI-funded Vanguard study of multi-cancer detection tests—has started accruing patients through nine sites across the U.S.

July 25, 2025

Vol.51 No.29

By Sara Willa Ernst, Jacquelyn Cobb and Paul Goldberg

City of Hope brings evidence-based approaches to integrative oncology

The landscape of cancer care is evolving rapidly, with growing recognition that optimal patient outcomes require a whole-person care approach that goes beyond cytotoxic and targeted therapies.

July 25, 2025

Vol.51 No.29

By Richard T. Lee

Rucaparib maintenance therapy demonstrates PFS benefit for HRD-negative and HRD-positive ovarian cancer

YOU MAY BE INTERESTED IN

Andrea Werblin Reid’s unflinching poetry documents the realities of cancer care, clinical trials, and loss
Her collection, “To See Yourself As You Vanish,” will be published three years after her death

ACOG says it will no longer accept federal funding

Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program

In phase III trial, epcoritamab regimen improves PFS in R/R follicular lymphoma

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

City of Hope brings evidence-based approaches to integrative oncology

Renew today!

Subscriber content

Never miss an issue!

Login

Rucaparib maintenance therapy demonstrates PFS benefit for HRD-negative and HRD-positive ovarian cancer

YOU MAY BE INTERESTED IN

Andrea Werblin Reid’s unflinching poetry documents the realities of cancer care, clinical trials, and lossHer collection, “To See Yourself As You Vanish,” will be published three years after her death

ACOG says it will no longer accept federal funding

Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program

In phase III trial, epcoritamab regimen improves PFS in R/R follicular lymphoma

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

City of Hope brings evidence-based approaches to integrative oncology

Never miss an issue!

Login

Andrea Werblin Reid’s unflinching poetry documents the realities of cancer care, clinical trials, and loss
Her collection, “To See Yourself As You Vanish,” will be published three years after her death